Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4105 - An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective multicenter study


09 Oct 2016


Poster display


Pongwut Danchaivijitr


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


P. Danchaivijitr1, N. Ngamphaiboon2, C. Jiarpinitnun3, E. Sirachainan4, P. Pattaranutaporn3, J. Setakornnukul5

Author affiliations

  • 1 Medical Oncology Division, Department Of Medicine, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH
  • 2 Division Of Medical Oncology, Department Of Medicine, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 3 Radiation Oncology, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 4 Medicine, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 5 Radiation Oncology, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH


Abstract 4105


To date, there is no recommended optimal cumulative dose (OCD) of cisplatin in definitive chemoradiotherapy (CRT) for non-metastatic nasopharyngeal carcinoma (NPC). We conducted a retrospective study to determine a MCCD in NPC treated with CRT.


Histologically confirmed non-metastatic NPC patients treated at the Ramathibodi and Siriraj Hospitals between 2007 and 2015 were identified. Baseline patient characteristics, treatment modality and survivals were abstracted. The OCD of cisplatin >200 mg/m2 was used as a stratification dose level. Primary end point was 3-year survival (OS). The Kaplan-Meier with log-rank test were used for analysis. A p-value


Total of 289 NPC patients were included for analysis. Two hundred and thirty one patients received OCD of cisplatin >200 mg/m2, while 58 patients did not. Median age was 52 (range 17-75). Median radiation dose was 6996 cGY (range 1440-7840). Median cisplatin dose was 240 mg/m2 (range 75-361). There was no statistical difference in demographics between these 2 groups, except radiation interruption was more common in patients who received ODC of cisplatin >200 mg/m2 (27% vs 3%, p 


Our study demonstrated no significant difference in 3 year OS and DFS between OCD of cisplatin greater or lesser than 200 mg/m2. A prospective study comparing standard vs lower dose of cisplatin is warranted to minimize cisplatin related toxicity during chemoradiotherapy for NPC.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings